RxDoctor Payments Data

Mudassir Malik, MD

Advanced Heart Failure and Transplant Cardiology · Des Moines, IANPI 1457553653

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $1,976 of the $2,983 with a category attached, or 66.2%. Abbott accounts for 61.8% of it on its own, with 14 other manufacturers making up the rest. Reporting peaked in 2020 at $1,333 and has fallen 84.5% since, to $207 in 2025.

$2,983in general payments, 2019–2025

Across 93 payments — averaging $32.08 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abbott$2K
  • E.r. Squibb & Sons, L.L.C.$483
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$143
  • Astellas Pharma US Inc$75
  • Novartis$74
  • AstraZeneca$72
  • plus $294 from 9 others

What the payments were for

  • Travel & lodging$91831%
  • Food & beverage$1,97666%
  • Education$893%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

Too few advanced heart failure and transplant cardiology providers in Iowato place this figure against a meaningful peer group, so we don't.

Medicare billing

Part B allowed, 2024
$286,610
Medicare patients
1,601
Services billed
4,480

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban366$295,897
EntrestoSacubitril/Valsartan123$95,055
XareltoRivaroxaban64$62,683
Repatha SureclickEvolocumab39$26,511
JardianceEmpagliflozin22$19,601
BrilintaTicagrelor12$5,260
Ranolazine ErRanolazine92$4,976
Metoprolol Succinate427$3,615
Bumetanide126$2,773
Atorvastatin Calcium443$2,514
Potassium Chloride102$1,976
Diltiazem 24hr Er (Cd)Diltiazem Hcl109$1,749
Ezetimibe55$1,440
Losartan Potassium282$1,361
Amlodipine Besylate304$1,282

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$18$295,897366 claims
NovartisEntresto$74$95,055123 claims
Johnson & JohnsonXarelto$71$62,68364 claims
AstraZenecaBrilinta$72$5,26012 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few advanced heart failure and transplant cardiology providers in Iowaon file to place this against a meaningful peer group, so we don't.

Other advanced heart failure and transplant cardiology in Des Moines

See the full list for Iowa

Where these figures come from

Is this you, or does something look wrong? →